Literature DB >> 24641363

Overexpression of RUNX3 inhibits malignant behaviour of Eca109 cells in vitro and vivo.

Hua-Xia Chen1, Shuai Wang, Zhou Wang, Zhi-Ping Zhang, Shan-Shan Shi.   

Abstract

Runt-related transcription factor 3 (RUNX3) is a tumor suppressor gene whose reduced expression may play an important role in the development and progression of esophageal squamous cell cancer (ESCC). The aim of this study was to investigate the clinical relevance of RUNX3 in ESCC patients and effects of overexpression on biological behaviour of Eca109 cells in vitro and in vivo. Immunohistochemistry was performed to detect the clinical relevance of RUNX3 and lymph node metastasis in 80 ESCC tissues and 40 non-cancerous tissues using the SP method. RT-PCR and Western blotting were applied to assess the RUNX3 level and verify the Eca109 cell line with stable overexpression. Localization of RUNX3 proteins was performed by cell immunofluorescence. CCK-8 and Scrape motility assays were used to determine proliferation and migration and the TUNEL assay to analyze cell apoptosis. Invasive potential was assessed in cell transwell invasion experiments. In nude mice, tumorigenesis in vivo was determined. Results showed decreased expression of RUNX3 in esophageal tissue to be significantly related to lymph node metastasis (LNM) (P<0.01). In addition, construction of a recombinant lentiviral vector and transfection into the human ESCC cell line Eca109 demonstrated that overexpression could inhibit cell proliferation, migration and invasion, and induce apoptosis. The in vivo experiments in mice showed tumorigenicity and invasiveness to be significantly reduced. Taken together, our studies indicate that underexpression of RUNX3 in human ESCC tissue is significantly correlated with progression. Restoration of RUNX3 expression significantly inhibits ESCC cells proliferation, migration, invasion and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24641363     DOI: 10.7314/apjcp.2014.15.4.1531

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy.

Authors:  Mo Shi; Zhou Wang; Xiang-Yan Liu; Dong Chen
Journal:  Med Oncol       Date:  2014-11-13       Impact factor: 3.064

2.  The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line.

Authors:  Ali Golestan; Zahra Mojtahedi; Ghasem Ghalamfarsa; Maryam Hamidinia; Mohammad Ali Takhshid
Journal:  Iran J Med Sci       Date:  2015-09

3.  Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.

Authors:  Fang Zheng; Jingjing Wu; Shunyu Zhao; Qingmei Luo; Qing Tang; LiJun Yang; Liuning Li; WanYing Wu; Swei Sunny Hann
Journal:  J Exp Clin Cancer Res       Date:  2015-05-07

4.  Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis.

Authors:  Dandan Fu; Xiangfeng Song; Hua Hu; Min Sun; Zhanguo Li; Zhongwei Tian
Journal:  Mol Med Rep       Date:  2016-04-12       Impact factor: 2.952

5.  RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.

Authors:  De-Jun Li; Mo Shi; Zhou Wang
Journal:  Thorac Cancer       Date:  2016-06-20       Impact factor: 3.500

6.  Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9.

Authors:  Xuchun Che; Rong Lu; Zheng Fu; Yajun Sun; Zhi-Feng Zhu; Jin-Ping Li; Song Wang; Jing Jia; Qing Wang; Zhi Yao
Journal:  Drug Des Devel Ther       Date:  2018-10-09       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.